Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E
…a functional protein. They are short man-made pieces of genetic material designed to bind to a specific target messenger, RNA (mRNA). The Food and Drug Administration has approved ASO-based treatments…
CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO
…treatments for rare diseases, will take the helm of the patient-led nonprofit as it moves to the next phase of its search for a cure for CMT. Dr. Bruhn brings…
October 2023 Community Statement from Novartis
“The CMTA welcomes this community update from Novartis and applauds its leading role in the development of treatments for CMT. The CMTA has been maintaining regular contact, providing support and…
Understanding Charcot-Marie-Tooth Disease in Children
…no approved treatments for CMT. Understanding CMT in Children Children with CMT sometimes take longer to reach physical milestones, such as walking, hopping, jumping with two feet, or getting up…
CMT4 Research
…the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, for undertaking a CMT4A gene therapy project. Taysha and the CMTA will…
REPORT CONCEPTSPREADS72
…will continue to be moni- tored for one year after treatment. CMT4A mouse models have also been treated with the gene therapy and are currently being assessed to measure treatment…
2021_Spring_CMTA_Report
…depressing: Some great researchers were working on CMT, but because there were no pharmaceutical companies involved, the research wasn’t being translated to treatments. HOW DID WE GET FROM THERE TO…
Breakthrough Guide to Orthopedic Surgery for CMT
Download a PDF Copy The Charcot-Marie-Tooth Association (CMTA) is thrilled to share with you a first-of-its kind article entitled, “A Consensus Statement on The Surgical Treatment of Charcot-Marie-Tooth Disease.” Published…
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
…Laura Feltri will be deeply missed.” Dr. Feltri was a dedicated supporter of our mission to support the development of new treatments for CMT, to improve the quality of life…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]